Abdi Ibrahim becam e the first Turkish company to figure am ong th e The Worlds Top 100 Pharm aceutical

Companies in 2007.
Established in 1912, Abdi Ibrahim is one of the most prominent industrial companies in Turkey. The Company has maintained its market leadership in turnover and unit sales for the past eight consecutive years. With a production capacity of 280 million packs, the Company manufactures solid forms, semi- solid forms and liquids using state-of-the-art, contemporary and environmentally friendly technologies. Of the total production, 60% consists of in-licensed original products and 40% of generics. The production facility also services international customers through contract manufacturing. Abdi Ibrahims facilities are accredited and th e Company holds cGMP and cGLP certifications valid in the EU. Abdi Ibrahim currently exports an Asthma product to three companies in Central and Eastern Europe and will export blockbuster cardiovascular product in Italy, France, Netherlands, Germany and Belgium with one of the worlds leading generics company. Abdi Ibrahims product portfolio is the largest in the sector, providing solutions in therapeutic areas including: Alimentary and metabolism, blood and blood forming organs, cardiovascular system, dermatology, genito-urinary system, systemic hormones, anti-infectives, musculoskeletal system, nervous system, respiratory system and sensory organs. Working with almost 30 licensors and developing its own products, the Company manufactures and markets 150 brands and 250 products. The Company has been known throughout the years for a continuous investment strategy, which has led to exponential growth. In the past twenty years, Abdi Ibrahim has invested over $237 million in its operations, including the inauguration of Turkeys first pharmaceutical R&D Centre in 2008. Abdi Ibrahim focuses its R&D efforts on the development of value-added generics, such as oral dispersible tablet forms, sustained release forms and new fixed-dose combination drugs, that enhance patient treatment compliance and efficacy. The Company has submitted 28 international paten t applications between 2008 and 2011. Abdi Ibrahims Regulatory team prepares the registration dossiers in CTD format, making use of the e-CTD tool, which allows for Marketing Authorizations to be obtained in regulated markets such as th e EU. The Company has several granted Marketing Authorizations to its name in UK, France, Netherlands, Belgium and Germany. The R&D Centre is also experienced in contract development for third parties and co-development projects with international partners. Currently, there are almost 10 products, which are being co-developed at Abdi Ibrahim with global partners. Abdi Ibrahim was the first Turkish company to be ranked one of the worlds top 100 pharmaceutical companies in 2007 and has been a global player for many years. Wit h exports to over 20 count ries, the Company operate s internationally in four regions: Europe, CIS & Balkans, Middle East - North Africa (MENA) and Far East & Sub Saharan Africa. Additionally the results from Abdi Ibrahims R&D team in t he form of CTD dossiers are being promoted on a global scale through licensing. International expansions are managed by the representative office in London in support of the relevant management team located in all four regions. The Company not only provides the highest employment in the industry with almost 3500 employees, but also has the largest sales and marketing team of about 2000 medical representatives. Abdi Ibrahim has the vision to expand its global position while maintaining its leadership in Turkey. 1912 >The first pharmacy was established in Istanbul. 1916 >The pharmacy launched th e production of proprietary medicines: Power Syrup (Restorative), Abdi Ibrahim Mushil Sekeri (Purgative Candy), Bromo-Valerin Nadir (Quasi Valebrom Le Grand). 191 9 >Abdi Ibrahims first pharmaceutical factory was established.> The Company launched the first ready-made drugs production. 19 39 >The second generation took over the management of the Company; the period of Pharmacist Ibrahim Hayri Barut commenced. 1952 >The laboratories were moved to its new location in Vefa district of Istanbul.

1975 >The Company was renamed Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. 19 81 >The third generation took over th e management; the period of Pharmacist Nezih Barut commenced. 1994 >The foundation of Abdi Ibrahim production facilities in Esenyurt. 1999 >The Company made its first global move into Algeria. 2000 >The Companys production facilities utilizing cGMP (current Global Manufacturing Practices) standards commenced operations. 2003 >Abdi Ibrahim became the sector leader in terms of turnover and unit sales.>The construction of the R&D Centre began. 2004 >The Companys EU GMP certificat e was approved by Dutch health authorities.>The global e xpansion process continued in Lebanon, Kazakhstan and Russia. 2005 >The Company expanded its global operations to Vietnam, Ukraine and Azerbaijan. 2007 >The R&D Centre, with GMP and GLP certificates, commenced operations.>The Company became th e first Turkish company to figure among the The Worlds Top 100 Pharmaceutical Companies.>Abdi Ibrahim Primary School was established.>Abdi Ibrahim Tower commenced operations. 2008 >The first accredited R&D Centre in the sector commenced operations.>The corporate identity was renewed. 2009 >Abdi Ibrahim became the sector leader with a total of 24 pat e nt applications.>Abdi Ibrahim London Office was established.>Global expansion continued with operations in Iraq, Jordan and Yemen.>The R&D Centre opened its doors in Esenyurt, Istanbul. 20 1 0 >Abdi Ibrahim Logistics Centre commenced operations in Esenyurt, Istanbul.>Abdi Farma was founded in Portugal. 2011 >Expansion outside Turkey continued in Poland, Hungary, Slovakia, France, Italy, Germany, the Netherlands, Greece, South Korea, the UK and Turkmenistan.

R&D Ce ntre
Our multi-disciplinary R&D Centre is located in Istanbul. It is spread across a total area of 13.500 sqm. With an investment in excess of USD 40 million, the Centre is equipped with the latest analytical laboratory and scale-up technology.

R&D Capability
Our development activities range from preformulation studies and progress through analytical development, formulation and process optimization to pilot scale and clinical manufacturing for Bioequivalence studies. We have experience in the following galenical forms: Immediate release, controlled release tablets Orally Disintegrating Tablets Immediate, controlled or sustained release capsules Ophthalmic dosage forms and nasal sprays Parenteral forms Semi-liquid forms Oral liquids and suspensions, semi-liquid forms

Abdi Ibrahims R&D Centre is the first accredited pharmaceutical R&D centre in Turkey. The Scientific and Technological Council of Turkey (TUBITAK) has recognized and funded several of our innovative drug development projects in the recent past. Our research and development activities continuously create intellectual property. Most of Abdi Ibrahims leading brands in Turkey are created as a result of our in-house developments.

Co-Development and Partnering

We believe that collaborative research and development is vital for accelerated growth. Abdi Ibrahim is always looking for national and international opportunities for R&D programs and partnerships. We have successfully implemented several co-development projects with market leaders in regulated markets such as EU and US. Our R&D team has extensive international experience. Most of our highly experienced employees possess M. Sc and Ph Ds. from leading reputable universities. Abdi Ibrahim also has a dedicated Technology Transfer Team to meet increasing technology transfer needs from R&D to production site in a cost efficient and effective manner. All research and development activities conducted in our R&D Centre meet cGMP and cGLP requirements.

GMP Manufac turing Fac ility

Our manufacturing facility in Istanbul is the soul of our existence and expansion. Established in an area of 87.000 sqm with an annual production capacity of 280 million boxes, the facility bears international regulatory approvals and positions such as to allow the Company to offer manufacturing solutions to partners all across the globe.

A S napshot of Our Facility

The latest technology in compliance with current Good Manufacturing (cGMP) and Laboratory (cGLP) practices requirements are applied. The focus is on contemporary and environment-friendly technologies. For safety the OHSAS 18001 certificate has been obtained and for being environmental- friendly ISO 14001 certificate has been granted. Large quantities of products for companies such as Astra Zeneca, GSK, Servier and Bayer have been manufactured. The manufacturing facility can handle Liquid & Semi-Solids and Oral Solids. In the Liquid & Semi-Solid production department, oral drops, syrups, suspensions, lotions, sprays, ointments, creams, gels and suppositories are manufactured. In the Solid Packaging department, tablets, capsules, powder for dry suspension and sachets are manufactured. Large capacity granulators and coating equipment are present. Dry mixing, dry granulation, top spray granulation and conventional wet granulation are used. There are seven high capacity-coating machines. There is a high level of automation for manufacturing and packaging. The latest systems and equipment, such as pharmacode readers, automatic case packing and labeling, are used. There are high capacity and high speed blistering machines, which can handle Alu-Alu as well as Alu PVC. More than 100 focused, experienced and well-equipped professionals work in the quality control department. More than 4,500 batches of solid and liquid products were manufactured and analyzed between 2008 and 2009. More than 240 high technology analytical equipments are used in the laboratories; such as 16 UPLCs, 31 HPLCs, 11 dissolution testers , 6 gas chromatographers, 7 spectrophotometers, 11 pH meters, laser particle size analyzer, particle pore size analyzer, atomic absorption analyzer. The professional and qualified quality assurance team manages compliance, handling of complaints, change controls, deviations, training, documentation, and implementation of validation.